KOD

Kodiak Sciences Inc.

A clinical-stage biotech developing next-generation medicines for retinal diseases that cause blindness, aiming for longer-lasting anti-VEGF eye injections with candidates like Zenkuda (tarcocimab tedromer) and the bispecific KSI-501. Founded in 2009 as Oligasis and renamed Kodiak Sciences in 2015, the company takes its name from Alaska's mighty Kodiak bear — and fittingly, its Swiss manufacturing plant is called "Ursus," the Latin word for bear.

Recent Activity

Show $

2026Q2

1 sell

Polen Capital ManagementTRIM

-5.9K shares(-14.2%)

Polen Capital ManagementTRIM

-5.9K shares(-14.2%)

2026Q1

1 buy

Polen Capital ManagementADD

+14 shares(+0.0%)

Polen Capital ManagementADD

+14 shares(+0.0%)

Loading more activity...